Citizens raised the firm’s price target on Hinge Health (HNGE) to $80 from $65 and keeps an Outperform rating on the shares. Hinge Health is seeing strong momentum with accelerating billings and revenue growth, expanding margins, and broad adoption among major U.S. payers and PBMs, supported by a durable distribution moat, successful hardware-enabled care delivery, and new product expansion into broader pain and chronic condition management, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Earnings Call Signals Profitable Growth
- Hinge Health Lifts 2026 Outlook After Record Quarter
- Hinge Health Buy Rating Reiterated on Growth Momentum and Migraine Expansion, Price Target Maintained at $72
- Analyst Reiterates Buy on Hinge Health, Citing Near‑Term Outperformance Potential and Long‑Term Growth from New Migraine Care Program
- Hinge Health launching migraine treatment program, WSJ reports